Crescent Biopharma, Inc. (CBIO) stock

CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 10/30

$14.15−0.22 (-1.53%)

Close on Nov 13, 2026Market cap $525.59MP/E –Yield –

Crescent Biopharma total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Crescent Biopharma's total debt was $0 at Dec 31, 2025. For fiscal 2025 it was $0, down 100.0% from the year before.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$0	-100.0%
FY2024	Dec 31, 2024	$37.48M	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q4 FY2025	Dec 31, 2025	$0	–
Q3 FY2025	Sep 30, 2025	$0	–
Q2 FY2025	Jun 30, 2025	$0	–
Q4 FY2024	Dec 31, 2024	$37.48M	–

Parsed from the XBRL in Crescent Biopharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-100 reverse split on Jun 16, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CBIO.

Advertisement
300 × 250

See a number that looks wrong?